DNA methylation is a fundamental epigenetic modification that plays a critical role in the regulation of gene expression, chromatin structure, and genome stability. It involves the covalent addition of a methyl group to the 5-carbon position of cytosine residues within CpG dinucleotides, leading to the formation of 5-methylcytosine. Under normal physiological conditions, DNA methylation contributes to essential biological processes such as cell differentiation, genomic imprinting, and X-chromosome inactivation.
However, in cancer cells, these methylation patterns become profoundly altered. Aberrant DNA methylation — characterized by hypermethylation of tumor suppressor gene promoters and global hypomethylation — is now recognized as a hallmark of cancer. These epigenetic disruptions lead to gene silencing, oncogene activation, and increased genomic instability, driving tumor initiation and progression.
In this article, we will explore in depth the mechanisms of DNA methylation, the enzymes involved, and the molecular alterations observed in cancer cells. We will also discuss how these epigenetic changes contribute to tumorigenesis, their potential as diagnostic biomarkers, and the emerging therapeutic strategies targeting DNA methylation in oncology.
Molecular Basis of DNA Methylation
At the molecular level, DNA methylation refers to the enzymatic addition of a methyl group (–CH₃) to the 5-carbon position of cytosine residues within CpG dinucleotides, forming 5-methylcytosine (5mC). This covalent modification, which does not alter the DNA sequence itself, represents a key epigenetic mechanism for controlling gene activity and maintaining chromatin stability.
The process is catalyzed by a family of enzymes known as DNA methyltransferases (DNMTs). Among them, DNMT1 is responsible for maintenance methylation, faithfully copying existing methylation patterns onto the newly synthesized DNA strand during replication. In contrast, DNMT3A and DNMT3B perform de novo methylation, establishing new methylation marks during embryonic development or in response to environmental cues. These enzymes rely on S-adenosylmethionine (SAM) as a universal methyl donor.
Methylation occurs predominantly in CpG islands, which are cytosine–guanine-rich regions often located near gene promoters. In normal cells, these regions remain largely unmethylated to allow transcription. However, in cancer cells, aberrant CpG island methylation leads to transcriptional repression of tumor suppressor genes.
Complementing this process is DNA demethylation, which can occur passively (through replication without maintenance methylation) or actively, via ten–eleven translocation (TET) enzymes — TET1, TET2, and TET3. These enzymes oxidize 5-methylcytosine to 5-hydroxymethylcytosine, initiating a stepwise removal of methyl groups and restoration of unmethylated cytosine.
Together, the coordinated action of DNMTs and TET enzymes maintains a delicate balance between methylation and demethylation. Disruption of this equilibrium in cancer cells results in widespread epigenetic deregulation, driving oncogenic transformation and altered gene expression patterns.
Aberrant DNA Methylation in Cancer Cells
In healthy cells, DNA methylation patterns are tightly regulated to preserve genomic integrity and normal gene expression. However, in cancer cells, these epigenetic patterns become profoundly disrupted, giving rise to aberrant DNA methylation, which is now considered one of the earliest and most consistent molecular hallmarks of tumorigenesis.
Two major forms of methylation abnormalities are observed: hypermethylation and hypomethylation.
Hypermethylation of Tumor Suppressor Genes
Promoter hypermethylation involves the excessive methylation of CpG islands located in the promoter regions of critical tumor suppressor genes. This modification leads to chromatin condensation and the transcriptional silencing of genes essential for cell cycle control, DNA repair, and apoptosis.
Examples include the methylation-induced inactivation of CDKN2A (p16), MLH1, BRCA1, RASSF1A, and GSTP1, which results in uncontrolled proliferation and resistance to apoptosis. Such epigenetic gene silencing acts functionally equivalent to genetic mutations or deletions, effectively disabling tumor suppressor pathways.
Global and Gene-Specific Hypomethylation
Conversely, global DNA hypomethylation — the loss of methyl groups across large genomic regions — contributes to genomic instability and chromosomal rearrangements. Hypomethylation often occurs in repetitive sequences, transposable elements, and proto-oncogenes, leading to their aberrant activation. This phenomenon can reactivate oncogenic pathways and promote metastasis by inducing gene overexpression and loss of imprinting.
Together, hypermethylation of tumor suppressor genes and hypomethylation of oncogenic sequences represent a dual mechanism of epigenetic deregulation that drives cancer initiation and progression. These complementary processes reshape the cancer epigenome, altering gene expression networks and reinforcing malignant phenotypes.
Mechanisms Driving Aberrant Methylation Patterns
The establishment and maintenance of DNA methylation patterns are dynamic processes regulated by a complex network of enzymatic, genetic, and environmental factors. In cancer cells, this regulatory balance becomes disrupted, resulting in abnormal methylation landscapes that promote oncogenic transformation.
Altered Activity of DNA Methyltransferases and TET Enzymes
Abnormal expression or mutation of DNA methyltransferases (DNMT1, DNMT3A, DNMT3B) is one of the key drivers of epigenetic instability. Overexpression of DNMTs has been observed in several cancers, including colorectal, breast, and lung carcinomas, leading to aberrant promoter hypermethylation and silencing of tumor suppressor genes. Conversely, loss or mutation of TET enzymes (TET1, TET2, TET3) disrupts active DNA demethylation, reducing levels of 5-hydroxymethylcytosine and favoring hypermethylated states.
Genetic, Metabolic, and Environmental Influences
Multiple external and internal factors can modulate methylation enzymes. Oxidative stress and chronic inflammation generate reactive oxygen species that alter DNMT and TET function. Likewise, deficiencies in folate, vitamin B12, or S-adenosylmethionine (SAM) affect methyl group availability and contribute to global hypomethylation. Moreover, oncogenic mutations in metabolic enzymes such as IDH1 and IDH2 can impair TET-mediated demethylation by producing 2-hydroxyglutarate, an oncometabolite that inhibits dioxygenase activity.
Cross-Talk with Histone Modifications and Chromatin Remodeling
DNA methylation is intricately connected to histone modification and chromatin structure. Methylated DNA recruits methyl-binding domain (MBD) proteins, which attract histone deacetylases (HDACs) and chromatin remodeling complexes. This leads to heterochromatin formation, resulting in long-term gene silencing. In cancer, this cooperative mechanism reinforces transcriptional repression of tumor suppressor loci.
Epigenetic Reprogramming in Tumorigenesis
During malignant transformation, cells undergo extensive epigenetic reprogramming, resembling developmental reprogramming but occurring in an uncontrolled manner. Aberrant DNMT and TET activity, combined with histone modification dysregulation, reshapes the cancer cell’s epigenetic landscape, establishing heritable silencing of key regulatory genes that sustain the malignant phenotype.
Altogether, these interconnected molecular events underscore that aberrant DNA methylation in cancer is not a random occurrence but the outcome of systemic epigenetic dysregulation, linking environmental stress, metabolism, and chromatin architecture to tumor biology.
Epigenetic Plasticity and Gene Regulation
Cancer cells exhibit remarkable epigenetic plasticity, enabling them to reversibly switch gene expression programs in response to environmental or therapeutic pressures. This flexibility contributes to drug resistance, metastatic potential, and tumor heterogeneity. Advanced techniques such as bisulfite sequencing, methylation-specific PCR (MSP), and methylated DNA immunoprecipitation sequencing (MeDIP-seq) now allow high-resolution profiling of methylation patterns across cancer genomes, offering insights into gene regulatory alterations and their clinical significance.
DNA Methylation as a Biomarker for Cancer Diagnosis and Prognosis
One of the most promising applications of DNA methylation research lies in its use as a biomarker for cancer detection, prognosis, and therapeutic monitoring. Because aberrant DNA methylation occurs early during tumorigenesis and remains highly stable, it serves as a reliable molecular signature for identifying malignant cells across diverse cancer types.
Methylation Signatures in Cancer Diagnosis
Aberrant methylation of specific tumor suppressor genes provides a basis for early cancer detection. For instance, methylation of the SEPT9 gene in plasma DNA is a clinically validated biomarker for colorectal cancer screening. Similarly, GSTP1 methylation is highly specific for prostate cancer, while RASSF1A and CDKN2A (p16) methylation patterns are frequently observed in lung, breast, and liver cancers. These methylation events can be detected using highly sensitive molecular assays such as methylation-specific PCR (MSP) and next-generation sequencing-based methylome analysis.
Circulating Methylated DNA in Liquid Biopsies
The stability of methylated DNA fragments in the bloodstream has enabled the development of liquid biopsy techniques. These approaches allow non-invasive detection of circulating tumor DNA (ctDNA) methylation profiles, offering a powerful tool for early diagnosis, minimal residual disease monitoring, and treatment response assessment. Methylation analysis of ctDNA is particularly advantageous because it captures tumor heterogeneity and dynamic changes during disease progression.
Prognostic and Predictive Value of Methylation Profiles
Methylation patterns also carry prognostic significance, correlating with tumor stage, aggressiveness, and patient outcome. For example, hypermethylation of the MGMT promoter in glioblastoma is associated with increased sensitivity to alkylating agents, while BRCA1 methylation status can predict responsiveness to PARP inhibitors. Integrating methylation markers with genomic and transcriptomic data allows clinicians to better stratify patients and tailor personalized therapies.
Targeting DNA Methylation — Epigenetic Therapy in Cancer
Because DNA methylation is a reversible epigenetic modification, it represents a compelling target for cancer therapy. The development of epigenetic drugs that can restore normal methylation patterns has opened new avenues in the treatment of malignancies, particularly those driven by promoter hypermethylation and gene silencing.
DNMT Inhibitors: Azacitidine and Decitabine
The first class of drugs designed to reverse abnormal DNA methylation are DNA methyltransferase inhibitors (DNMTis). Two cytidine analogs — azacitidine (5-azacytidine) and decitabine (5-aza-2′-deoxycytidine) — are currently approved for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). These agents become incorporated into DNA during replication, where they irreversibly trap DNMT enzymes, leading to their degradation and passive demethylation of the genome. This reactivates silenced tumor suppressor genes, restoring normal differentiation and apoptosis pathways.
Combination Epigenetic Therapies
Recent research has focused on combining DNMT inhibitors with other epigenetic modulators, such as histone deacetylase inhibitors (HDACis), to achieve synergistic effects on chromatin reprogramming. Furthermore, integrating epigenetic therapy with chemotherapy, immunotherapy, or targeted molecular agents has shown promising results in overcoming resistance and enhancing treatment efficacy.
Emerging Therapeutic Strategies
Next-generation approaches aim to improve the specificity and safety of epigenetic interventions. Novel small molecules targeting TET enzyme regulation, SAM metabolism, and methyl-binding domain (MBD) proteins are under investigation. In addition, advances in CRISPR-based epigenetic editing — such as dCas9-TET1 or dCas9-DNMT3A fusion systems — allow precise locus-specific modulation of methylation patterns without altering the underlying DNA sequence. These strategies hold great potential for reprogramming oncogenic epigenomes with minimal off-target effects.
Clinical and Translational Perspectives
While DNMT inhibitors have demonstrated success in hematologic malignancies, their efficacy in solid tumors remains limited due to factors such as drug delivery, tumor microenvironment, and cellular heterogeneity.
Conclusion
DNA methylation stands at the core of epigenetic regulation in cancer, influencing gene expression, chromatin organization, and genomic stability. The balance between methylation and demethylation is crucial for maintaining cellular homeostasis, and its disruption contributes to tumor initiation, progression, and therapeutic resistance.
Understanding the mechanisms of DNA methylation in cancer cells has not only deepened our knowledge of tumor biology but also opened new diagnostic and therapeutic horizons.
References:
- Klutstein M, Nejman D, Greenfield R, Cedar H. DNA Methylation in Cancer and Aging. Cancer Res. 2016 Jun 15;76(12):3446-50. doi: 10.1158/0008-5472.CAN-15-3278.
- Zafon C, Gil J, Pérez-González B, Jordà M. DNA methylation in thyroid cancer. Endocr Relat Cancer. 2019 Jul;26(7):R415-R439. doi: 10.1530/ERC-19-0093.
- Huang W, Li H, Yu Q, Xiao W, Wang DO. LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond. J Exp Clin Cancer Res. 2022 Mar 15;41(1):100. doi: 10.1186/s13046-022-02319-z.
- Lee AV, Nestler KA, Chiappinelli KB. Therapeutic targeting of DNA methylation alterations in cancer. Pharmacol Ther. 2024 Jun;258:108640. doi: 10.1016/j.pharmthera.2024.108640.
- Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer. Trends Genet. 2021 Nov;37(11):1012-1027. doi: 10.1016/j.tig.2021.05.002.
